Abstract
Diseases of the cardiovascular system (CVS) are becoming more prevalent among people of working age, whose health status significantly affects the country's labor and economic resources. Official WHO statistics state that the mortality of the able-bodied population from various types of diseases of the CVS is increasing every year. More than 75% of deaths from cardiovascular diseases (CVD) occur in countries with medium and low GDP. In Ukraine, almost two-thirds of the population (68%) of the total morbidity rate dies from CVD. Therefore, the ongoing monitoring and analysis of the proposals of medicine presented on the pharmaceutical market (PM) of Ukraine for the treatment of CVD is topical. Aim. To undertake a retrospective analysis of medicines market recommended for the treatment of CVD in Ukraine.Results. In retrospective analysis of MD for treatment of CVD in the PM of Ukraine, it was revealed that on average, foreign medicines represented on the market by 7.6 % more than the domestic manufactured medicines. While deviding the medications into domestic and foreign groups for study, it was revealed that during the period 2013-2017 the largest group of foreign medicine offered was the group C09A – ACE inhibitors, the specific gravity was 23.46 % in 2017. The number of domestic medicines offered, it was founded that during 2014-2017 the greatest was the group B01A – antithrombotic agents, the specific gravity in 2017 – 26.71 %, respectively. When analysing the inspected sample according to the drug forms, it was identified a significant prevalence of medicine in the form of tablets – 88.88 %.Conclusions. In connection with the significant dominance of PM for foreign MD on the territory of Ukraine, the implementation of import substitution programs, as well as the development of reference pricing, in particular the reimbursement of the cost of medicines, to increase the level of access to medicines, is becoming particularly relevant.
Highlights
In Ukraine, almost two-thirds of the population (68 %) of the total morbidity rate dies from cardiovascular diseases (CVD)
The ongoing monitoring and analysis of the proposals of medicine presented on the pharmaceutical market (PM) of Ukraine for the treatment of CVD is topical
In retrospective analysis of MD for treatment of CVD in the PM of Ukraine, it was revealed that on average, foreign medicines represented on the market by 7.6 % more than the domestic manufactured medicines
Summary
In retrospective analysis of MD for treatment of CVD in the PM of Ukraine, it was revealed that on average, foreign medicines represented on the market by 7.6 % more than the domestic manufactured medicines. While deviding the medications into domestic and foreign groups for study, it was revealed that during the period 2013-2017 the largest group of foreign medicine offered was the group C09A – ACE inhibitors, the specific gravity was 23.46 % in 2017. The number of domestic medicines offered, it was founded that during 2014-2017 the greatest was the group B01A – antithrombotic agents, the specific gravity in 2017 – 26.71 %, respectively. When analysing the inspected sample according to the drug forms, it was identified a significant prevalence of medicine in the form of tablets – 88.88 %
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Upravlìnnâ, ekonomìka ta zabezpečennâ âkostì v farmacìï
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
